Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ortataxel in Advanced Renal Cell Cancer
NCT00039169Phase 2Unknown
- Sponsor
- Theradex Oncology
- Start
- Dec 2001
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ortataxel in renal cell carcinoma (RCC), sponsored by Theradex Oncology. Primary endpoint: Overall Tumor Response Rate. Status: unknown.
02
Drugs
ortataxel
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00039169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039169.